Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Status:
Completed

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis

Phase 2

Prolong Pharmaceuticals